Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate whether maintenance therapy with bevacizumab plus capecitabine, compared to bevacizumab alone, can further increase Progression-Free Survival (PFS) in patients showing objective response or stable disease following initial therapy with bevacizumab plus docetaxel.
Critère d'inclusion
- HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy